Cargando…

Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?

BACKGROUND: We investigated whether levosimendan prevents contrast medium nephrotoxicity with glycerol aggravation in rats. METHODS: Forty-eight Wistar albino rats were assigned to eight groups (n = 6 × 8). No medication was administered to group I (controls); glycerol (intramuscular injection of 25...

Descripción completa

Detalles Bibliográficos
Autores principales: Durur-Subasi, Irmak, Kose, Duygu, Yayla, Muhammed, Sirin, Busra, Karaman, Adem, Calik, Ilknur, Alper, Fatih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595362/
https://www.ncbi.nlm.nih.gov/pubmed/34786647
http://dx.doi.org/10.1186/s41747-021-00249-7
_version_ 1784600185838501888
author Durur-Subasi, Irmak
Kose, Duygu
Yayla, Muhammed
Sirin, Busra
Karaman, Adem
Calik, Ilknur
Alper, Fatih
author_facet Durur-Subasi, Irmak
Kose, Duygu
Yayla, Muhammed
Sirin, Busra
Karaman, Adem
Calik, Ilknur
Alper, Fatih
author_sort Durur-Subasi, Irmak
collection PubMed
description BACKGROUND: We investigated whether levosimendan prevents contrast medium nephrotoxicity with glycerol aggravation in rats. METHODS: Forty-eight Wistar albino rats were assigned to eight groups (n = 6 × 8). No medication was administered to group I (controls); glycerol (intramuscular injection of 25% glycerol, 10 mL/kg) group II; intravenous iohexol 10 mL/kg to group III; glycerol and iohexol to group IV; iohexol and intraperitoneal levosimendan 0.25 mg/kg to group V; glycerol, iohexol, and levosimendan 0.25 mg/kg to group VI; iohexol and levosimendan 0.5 mg/kg to group VII; and glycerol, iohexol, and levosimendan 0.5 mg/kg to group VIII. One-day water withdrawal and glycerol injection prompted renal damage; iohexol encouraged nephrotoxicity; levosimendan was administered 30 min after glycerol injection and continued on days 2, 3, and 4. The experiment was completed on day 5. Serum blood urea nitrogen (BUN) and creatinine levels, superoxide dismutase (SOD) activity, glutathione (GSH), malondialdehyde (MDA) levels, tumour necrosis factor-α (TNF-α), nuclear factor kappa ß (NFK-ß), interleukin 6 (IL-6), and histopathological marks were assessed. One-way analysis of variance and Duncan’s multiple comparison tests were used. RESULTS: Levosimendan changed serum BUN (p = 0.012) and creatinine (p = 0.018), SOD (p = 0.026), GSH (p = 0.012), and MDA (p = 0.011). Levosimendan significantly downregulated TNF-α (p = 0.022), NFK-ß (p = 0.008), and IL-6 (p = 0.033). Histopathological marks of hyaline and haemorrhagic cast were improved in levosimendan-injected groups. CONCLUSION: Levosimendan showed nephroprotective properties due to its vasodilator, oxidative distress decreasing and inflammatory cytokine preventing belongings.
format Online
Article
Text
id pubmed-8595362
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85953622021-12-02 Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats? Durur-Subasi, Irmak Kose, Duygu Yayla, Muhammed Sirin, Busra Karaman, Adem Calik, Ilknur Alper, Fatih Eur Radiol Exp Original Article BACKGROUND: We investigated whether levosimendan prevents contrast medium nephrotoxicity with glycerol aggravation in rats. METHODS: Forty-eight Wistar albino rats were assigned to eight groups (n = 6 × 8). No medication was administered to group I (controls); glycerol (intramuscular injection of 25% glycerol, 10 mL/kg) group II; intravenous iohexol 10 mL/kg to group III; glycerol and iohexol to group IV; iohexol and intraperitoneal levosimendan 0.25 mg/kg to group V; glycerol, iohexol, and levosimendan 0.25 mg/kg to group VI; iohexol and levosimendan 0.5 mg/kg to group VII; and glycerol, iohexol, and levosimendan 0.5 mg/kg to group VIII. One-day water withdrawal and glycerol injection prompted renal damage; iohexol encouraged nephrotoxicity; levosimendan was administered 30 min after glycerol injection and continued on days 2, 3, and 4. The experiment was completed on day 5. Serum blood urea nitrogen (BUN) and creatinine levels, superoxide dismutase (SOD) activity, glutathione (GSH), malondialdehyde (MDA) levels, tumour necrosis factor-α (TNF-α), nuclear factor kappa ß (NFK-ß), interleukin 6 (IL-6), and histopathological marks were assessed. One-way analysis of variance and Duncan’s multiple comparison tests were used. RESULTS: Levosimendan changed serum BUN (p = 0.012) and creatinine (p = 0.018), SOD (p = 0.026), GSH (p = 0.012), and MDA (p = 0.011). Levosimendan significantly downregulated TNF-α (p = 0.022), NFK-ß (p = 0.008), and IL-6 (p = 0.033). Histopathological marks of hyaline and haemorrhagic cast were improved in levosimendan-injected groups. CONCLUSION: Levosimendan showed nephroprotective properties due to its vasodilator, oxidative distress decreasing and inflammatory cytokine preventing belongings. Springer International Publishing 2021-11-17 /pmc/articles/PMC8595362/ /pubmed/34786647 http://dx.doi.org/10.1186/s41747-021-00249-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Durur-Subasi, Irmak
Kose, Duygu
Yayla, Muhammed
Sirin, Busra
Karaman, Adem
Calik, Ilknur
Alper, Fatih
Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
title Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
title_full Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
title_fullStr Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
title_full_unstemmed Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
title_short Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
title_sort does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595362/
https://www.ncbi.nlm.nih.gov/pubmed/34786647
http://dx.doi.org/10.1186/s41747-021-00249-7
work_keys_str_mv AT durursubasiirmak doesthecardiovasculardruglevosimendanpreventiodinatedcontrastmediumnephrotoxicitywithglycerolaggravationinrats
AT koseduygu doesthecardiovasculardruglevosimendanpreventiodinatedcontrastmediumnephrotoxicitywithglycerolaggravationinrats
AT yaylamuhammed doesthecardiovasculardruglevosimendanpreventiodinatedcontrastmediumnephrotoxicitywithglycerolaggravationinrats
AT sirinbusra doesthecardiovasculardruglevosimendanpreventiodinatedcontrastmediumnephrotoxicitywithglycerolaggravationinrats
AT karamanadem doesthecardiovasculardruglevosimendanpreventiodinatedcontrastmediumnephrotoxicitywithglycerolaggravationinrats
AT calikilknur doesthecardiovasculardruglevosimendanpreventiodinatedcontrastmediumnephrotoxicitywithglycerolaggravationinrats
AT alperfatih doesthecardiovasculardruglevosimendanpreventiodinatedcontrastmediumnephrotoxicitywithglycerolaggravationinrats